European Study Group for Pancreatic Cancer (ESPAC) - Trial 3. Adjuvant Chemotherapies in Resectable Pancreatic Cancer
|III||Treatment||Closed||University of Liverpool and RLBUHT|| Eudract No: N/A
Isrctn No: ISRCTN37494643
Pancreatic cancer is one of the major causes of cancer death in Central and Northern European countries as well as in North America, Australasia and Japan 1. Initial treatment involves surgical resection Despite recent improvements in resection rates for localised pancreatic cancer, long-term survival following surgery alone remains poor with a median of 11-15 months, 2-year survival of 20-40% and 5-year survival of around 10% 2, 3. ESPAC-3 was formulated as a result of the ESPAC-1 study.
1. Parkin DM, Muir CS, Whelan SL, Sao Y-T, Ferlay J, in the adjuvant setting Powell J. (Eds). Cancer incidence in five continents. Vol VI. Lyon: International Agency for Research on Cancer 1992 (IARC Scientific Publications No. 120) 2. Neoptolemos JP, Russell RCG, Bramhall S, Theis B for the UK Pancreatic Cancer Group. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of pancreatic specialist units. Br J Surg 1997; 84: 1370-6. 3. Beger HG, Link KH, Poch B, Gansauge F. Pancreatic cancer - recent progress in diagnosis and treatment. In: Neoptolemos JP, Lemoine NR (Eds). Pancreatic Cancer: Molecular and Clinical Advances. Oxford, 1996:227-35.
0151 794 8834
For patients with ductal adenocarcinoma of the pancreas randomised into the two-arm study:
For patients with ampullary or other pancreatic tumours randomised into the three-arm study:
Sorry there are currently no job vacancies
Some useful downloads: